Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
IMODIUM is an oral solution small-molecule antidiarrheal agent approved in 1984 by Johnson & Johnson. The drug addresses acute and chronic diarrhea across multiple etiologies. It represents a mature, well-established therapeutic option with broad OTC and Rx availability.
LOE-approaching lifecycle indicates smaller brand team focus on retention and market defense rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
Working on IMODIUM offers stability in a legacy asset but limited growth trajectory; roles are primarily defensive and focused on market share retention against generics. This position suits professionals seeking established product experience or those transitioning toward market access and brand defense strategies.
Worked on IMODIUM at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.